Monday, June 15, 2020 10:37:58 PM
Great call on the Hydroxy article, Investor!
Not looking so good for hydrocloriquine regarding COVID-19: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31180-6/fulltext
http://www.freerepublic.com/focus/f-news/3855927/posts
Lancet launched an independent peer review of the paper but when it came time for Surgisphere to put its cards on the table, it balked:
Our independent peer reviewers informed us that Surgisphere would not transfer the full dataset, client contracts, and the full ISO audit report to their servers for analysis as such transfer would violate client agreements and confidentiality requirements. As such, our reviewers were not able to conduct an independent and private peer review and therefore notified us of their withdrawal from the peer-review process…
Based on this development, we can no longer vouch for the veracity of the primary data sources. Due to this unfortunate development, the authors request that the paper be retracted.
Last week the Guardian published a follow-up report on Dr Sapan Desai, the founder of Surgisphere and the lead author of the retracted paper. He has had dozens of other papers published over the years, all of which are now receiving additional scrutiny:
Major institutions including Stanford University, which were described as research partners on the Surgisphere website, said they were not aware of any formal relationship with the company.
A study that formed the basis of Desai’s PhD may contain doctored images, according to expert claims, and the global medical publishing company Elsevier is conducting a review of his papers published in its journals.
Claims made by Desai about his qualifications gained since his medical degree have been called into doubt, including his claims to hold two PhDs, a master’s, and affiliations with major universities and colleges. Some of these affiliations have now been removed from his website and online profiles.
It looks like Dr. Desai’s entire history is full of fraudulent claims. His Wikipedia page was flagged 10 years ago because people noticed many of the claims about him were sourced to his own website.
It was only when this guy made international news that doctors who knew better noticed there was a problem. The result is not just the retraction of one paper but at least three so far and probably many more to come. Add to that the collapse of his company and significant damage to the reputations of everyone involved, including Lancet which should never have published this in the first place.
Not looking so good for hydrocloriquine regarding COVID-19: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31180-6/fulltext
http://www.freerepublic.com/focus/f-news/3855927/posts
Lancet launched an independent peer review of the paper but when it came time for Surgisphere to put its cards on the table, it balked:
Our independent peer reviewers informed us that Surgisphere would not transfer the full dataset, client contracts, and the full ISO audit report to their servers for analysis as such transfer would violate client agreements and confidentiality requirements. As such, our reviewers were not able to conduct an independent and private peer review and therefore notified us of their withdrawal from the peer-review process…
Based on this development, we can no longer vouch for the veracity of the primary data sources. Due to this unfortunate development, the authors request that the paper be retracted.
Last week the Guardian published a follow-up report on Dr Sapan Desai, the founder of Surgisphere and the lead author of the retracted paper. He has had dozens of other papers published over the years, all of which are now receiving additional scrutiny:
Major institutions including Stanford University, which were described as research partners on the Surgisphere website, said they were not aware of any formal relationship with the company.
A study that formed the basis of Desai’s PhD may contain doctored images, according to expert claims, and the global medical publishing company Elsevier is conducting a review of his papers published in its journals.
Claims made by Desai about his qualifications gained since his medical degree have been called into doubt, including his claims to hold two PhDs, a master’s, and affiliations with major universities and colleges. Some of these affiliations have now been removed from his website and online profiles.
It looks like Dr. Desai’s entire history is full of fraudulent claims. His Wikipedia page was flagged 10 years ago because people noticed many of the claims about him were sourced to his own website.
It was only when this guy made international news that doctors who knew better noticed there was a problem. The result is not just the retraction of one paper but at least three so far and probably many more to come. Add to that the collapse of his company and significant damage to the reputations of everyone involved, including Lancet which should never have published this in the first place.
Recent AVXL News
- Form 8-K - Current report • Edgar (US Regulatory) • 05/22/2026 12:15:26 PM
- Anavex Life Sciences Receives Expected Nasdaq Delinquency Notification • GlobeNewswire Inc. • 05/22/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2026 08:15:25 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2026 08:15:30 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 05/11/2026 08:30:22 PM
- CEO Transition and Delayed SEC Filing Put Anavex (AVXL) Leadership Changes in Focus • IH Market News • 05/06/2026 02:52:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2026 11:04:59 AM
- Anavex Life Sciences Board of Directors Appoints Former Senior Vice President of Clinical Development Terrie Kellmeyer, PhD, as Interim Chief Executive Officer • GlobeNewswire Inc. • 05/06/2026 11:00:00 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/01/2026 11:18:47 PM
- Anavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer’s Disease • GlobeNewswire Inc. • 04/14/2026 11:30:00 AM
- Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/07/2026 11:30:00 AM
- Anavex withdraws EU approval filing for Alzheimer’s therapy • IH Market News • 03/30/2026 12:39:26 PM
- Anavex Life Sciences Provides Comprehensive Regulatory Update • GlobeNewswire Inc. • 03/30/2026 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/25/2026 08:06:00 PM
- Anavex withdraws EU marketing application for Alzheimer’s therapy blarcamesine • IH Market News • 03/25/2026 02:06:58 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/25/2026 11:30:00 AM
- Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/23/2026 11:30:00 AM
- New Scientific Findings Highlight Hypothesis of Autophagy Failure as a Precursor of Amyloid Beta and Tau Pathology in Alzheimer’s Disease • GlobeNewswire Inc. • 03/20/2026 11:30:00 AM
- Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson’s Disease at AD/PD 2026 Conference • GlobeNewswire Inc. • 03/17/2026 11:30:00 AM
- Anavex Life Sciences to Present at the Citizens Life Sciences Conference • GlobeNewswire Inc. • 03/03/2026 12:30:00 PM
- Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference • GlobeNewswire Inc. • 02/25/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 11:07:01 AM
- Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors • GlobeNewswire Inc. • 02/23/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/09/2026 09:40:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2026 12:31:17 PM
